Our Perspectives
THREAD Blog
A look into the hyper-acceleration of life sciences with Sean Vassilaros
We are obviously concerned about the safety and efficacy of clinical research, but we also want to make sure we are going down the right path when it comes to the goal of life sciences: taking care of the patient. In fact, Sean Vassilaros, COO of THREAD uses the phrase, ‘appropriate-effort’ to discuss the matter when asked how he believed this process was able to be expedited. "We just learned in the last year, that if you use appropriate effort to bring something to production, you're allowed to move at lightning speed."
We Need Descriptive and Predictive Metrics for Advanced Trials - The Time is Now
If we continue to measure and monitor performance of decentralized trials using traditional metrics that don’t fit, we can never be sure how effective these studies are. DCTs and Hybrid DCTs are simply too different from site-based trials for older study metrics to fit well. Traditional studies rely on clinic visits, where doctors and clinical staff collect various types of data derived from participant interviews, lab tests, and point-of-care instruments (e.g. blood pressure cuffs, pulse oximeters, etc.). A standard metric used in these types of trials is time from visit to data entry.
Maximizing participant engagement in your clinical trial
Some estimates indicate 85% of trials are failing to recruit enough participants and 80% are delayed due to recruitment challenges and high dropout rates.1 This challenge has been long-standing within the industry, and the adoption of decentralized approaches offer a promising strategy towards maximizing participant recruitment.